TITLE

THYROID ANALOGS AS CHOLESTEROPENIC AGENTS

AUTHOR(S)
Hoff, H. Richard; Sperber, Robert J.; Fisch, Solomon; DeGraff, Arthur C.
PUB. DATE
February 1962
SOURCE
Angiology;Feb1962, Vol. 13 Issue 2, p94
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
d-Triiodothyronine was administered to four patients in a double-blind multiple dose study. Although this drug was found to be a potent cholesteropenic agent, it possessed sufficient adverse calorigenic activity to make further study hazardous in patients with coronary atherosclerosis. Sodium d-thyroxine was administered to 13 patients with hypercholesterolemia, including five patients with coronary artery disease. In the initial 6-week period of observation a statistically significant majority of all patients showed a decrease in the serum cholesterol level irrespective of whether they were receiving placebo or d-thyroxine. The substitution of drug for placebo produced no further depression of serum cholesterol in the ensuing 6-week period, but the substitution of placebo in the group initially receiving d-thyroxine, resulted in an average increase in serum cholesterol of 112 mg per cent, which was statistically significant. The results suggest that a modified study must be undertaken to establish more definitely whether or not d-thyroxine is an effective cholesteropenic agent in the desirable dose range. Of the five patients with coronary atherosclerosis, one noted an aggravation of angina and another developed an acute myocardial infarction while on the drug, although the agent cannot be definitely implicated.
ACCESSION #
16371465

 

Related Articles

  • ONE YEAR OF SODIUM DEXTROTHYROXINE THERAPY FOR HYPERCHOLESTEROLEMIA. Cohen, Burton M. // Angiology;Feb1962, Vol. 13 Issue 2, p69 

    Sodium dextrothyroxine, the sodium salt of the dextrorotatory isomer of thyroxine, was administered in daily oral doses ranging from 4 to 8 mg to 30 patients with hypercholesterolemic states for 52 weeks. A drop in serum cholesterol values was recorded in every patient, and averaged a reduction...

  • Effect of Dextro--isomers of Thyroid Hormones on Serum Cholesterol Levels in Euthyroid Hypercholesterolemic Patients. Hollister, Leo E.; Arons, Walter L. // Annals of Internal Medicine;Apr62, Vol. 56 Issue 4, p570 

    Reports on the possibility that dextro-isomers are effective in lowering serum lipids. Reduction of serum cholesterol levels by thyroid hormones in euthyroid as well as hypothyroid patients; Less thyroid hormonal activity of d-thyroxine than the levo-isomer.

  • CEREBROVASCULAR ACCIDENT.  // Review of Optometry;3/15/2005 Supplement, Vol. 142, p52A 

    This article reports that the cerebrovascular accident (CVA), also known as stroke or "brain attack," represents a sudden, focal disruption in circulation to the brain, and results in a corresponding loss of neurologic function. Men demonstrate a higher incidence than women, and increasing age...

  • Simple Screening of Pulmonary Artery Hypertension Using Standard Chest X Ray: An Old Technique, New Landmark. Mirsadraee, Majid; Nazemi, Saeed; Hamedanchi, Ali; Naghibi, Saeed // Tanaffos;2013, Vol. 12 Issue 3, p17 

    Background: Pulmonary artery hypertension (PAH) is difficult to diagnose because of its nonspecific symptoms. Although echocardiography can reliably and rapidly recognize the presence of pulmonary hypertension, chest X ray (CXR) is more widely used because of its availability. The objective of...

  • Practice Patterns for Pulmonary Arterial Hypertension: A Survey of 741 Chest Physicians. Roberts, Micah J.; Helman, Donald // Hawaii Medical Journal;Sep2009, Vol. 68 Issue 8, p191 

    Introduction Current pulmonary arterial hypertension (PAH) guidelines recommend altering medical management when a patient "deteriorates or fails to respond." Due do a lack of published data, PAH guidelines do not specifically define failure or response. The purpose of our study was to...

  • Sildenafil is useful in pulmonary arterial hypertension. Karadi, R. L. // Thorax;Feb2006, Vol. 61 Issue 2, p176 

    The abstract of the study "Sildenafil is useful in pulmonary arterial hypertension," by N. Galie, H.A. Ghofrani, A. Tarbicki and colleagues, is presented. The multicenter, double blind, placebo controlled study was performed in 278 patients with pulmonary arterial hypertension. The patients were...

  • Management of Primary Pulmonary Artery Sarcoma: Experience of a Single Center. Fernández-Golfín, Covadonga; Escribano, Pilar; Cortina, José; Tello, Rocío; Hernández, Felipe; López-Rios, Fernando; Jiménez, Juan Delgado; de la Calzada, Carlos Saenz // Angiology;Oct/Nov2008, Vol. 59 Issue 5, p636 

    Primary sarcoma of the pulmonary artery (PSPA) is extremely rare. Many cases are misdiagnosed as pulmonary arterial hypertension (PAH) because of chronic thromboembolic disease (CTD). Four cases of PSPA with the initial misdiagnosis are reported. The presence of a unique mass in the main...

  • Low-pressure pulmonary artery aneurysm presenting with pulmonary embolism: a case series.  // Journal of Medical Case Reports;2011, Vol. 5 Issue 1, p1 

    The article presents two case studies which focuses on patients with an idiopathic low-pressure pulmonary artery aneurysm (PAA) and a pulmonary embolism. Pulmonary artery aneurysm is associated with many serious complications and often difficult to diagnose. Significant primary or secondary...

  • Sitaxentan improves all SF-36 domains in PAH.  // PharmacoEconomics & Outcomes News;3/10/2007, Issue 523, p9 

    The article discusses research being done on the effect of sitaxentan treatment on the quality of life (QOL) of patients with pulmonary arterial hypertension. The study showed that sitaxentan seems to improve all QOL domains assessed by the Short-Form 36, with some domains achieving statistical...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics